{"metadata":{"generator":"Captivate","generatorVersion":"10.0.1","schemaVersion":"","author":"eviQ Education","title":"eQuiz - Classes of immunotherapy drugs","description":"project description","email":"eviqed@eviq.org.au","website":"https://education.eviq.org.au/","tags":"","thumbnail":"","source":"assets","durationInFrames":1284,"frameRate":30,"totalSlides":15,"width":1280,"height":800,"responsive":false,"scalable":false,"launchFile":"index_scorm.html"},"contentStructure":[{"id":"si15367","class":"TODO::Senthil","roles":{}},{"id":"si15398","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7002","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7013","class":"TODO::Senthil","title":"Immunotherapy drugs  ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7024","class":"TODO::Senthil","roles":{}},{"id":"si7026","class":"TODO::Senthil","roles":{}},{"id":"si7028","class":"TODO::Senthil","title":"Classes of  ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7039","class":"TODO::Senthil","title":"Version 1|March 2018 ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"SS_start_btn_1","class":"TODO::Senthil","instance":"SS_start_btn_1","title":"eQuiz ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7104","class":"TODO::Senthil","title":"eQuiz ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7123","class":"TODO::Senthil","title":"eQuiz ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"Slide4531","class":"Normal Slide","instance":"","thumbnail":"","children":["si15367","si15398","si7002","si7013","si7024","si7026","si7028","si7039","SS_start_btn_1","si7104","si7123"],"roles":{"slide":{"durationInFrames":147},"navigation":{"navid":"Slide4531"}}},{"id":"si15413","class":"TODO::Senthil","roles":{}},{"id":"si7578","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7593","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7602","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7613","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7622","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7642","class":"TODO::Senthil","roles":{}},{"id":"si7644","class":"TODO::Senthil","roles":{}},{"id":"SmartShape_2","class":"TODO::Senthil","instance":"SmartShape_2","title":"Before attempting this eQuiz, it is strongly recommended you review the associated eLearning guide.  The required pass mark for this eQuiz is 80%.  If you do not achieve the required 80% pass mark you may attempt the eQuiz again.  If you are unable to achieve the required pass mark after 3 attempts please speak to an experienced colleague or a member of your education team. Alternatively, you may submit an enquiry to  eviQ Education at eviqed@eviq.org.au (please include a screen shot of your question). ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"SmartShape_3","class":"TODO::Senthil","instance":"SmartShape_3","title":"Welcome to the eQuiz for Immunotherapies: Classes of immunotherapy drugs ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"BACKbtn_6","class":"TODO::Senthil","instance":"BACKbtn_6","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7699","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7718","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"NEXTbtn_7","class":"TODO::Senthil","instance":"NEXTbtn_7","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7773","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si7792","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"Slide7159","class":"Normal Slide","instance":"","thumbnail":"","children":["si15413","si7578","si7593","si7602","si7613","si7622","si7642","si7644","SmartShape_2","SmartShape_3","BACKbtn_6","si7699","si7718","NEXTbtn_7","si7773","si7792"],"roles":{"slide":{"durationInFrames":147},"navigation":{"navid":"Slide7159"}}},{"id":"si15431","class":"TODO::Senthil","roles":{}},{"id":"si15523","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"textData":{}}},{"id":"SmartShape_8","class":"TODO::Senthil","instance":"SmartShape_8","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"textData":{}}},{"id":"si8272","class":"TODO::Senthil","roles":{}},{"id":"si8195","class":"TODO::Senthil","title":"mAbs may be used as an immunotherapy or as a targeted therapy in the treatment of cancer. Which of the following is true about the use of mAbs as an immunotherapy? (select all that apply)  ","roles":{"textData":{}}},{"id":"si8210","class":"TODO::Senthil","title":" ","roles":{"textData":{}}},{"id":"si8214","class":"TODO::Senthil","title":"The mAb binds to antigens on the surface of tumour cells and mark the cell for destruction by the immune system. ","roles":{"textData":{}}},{"id":"si8214","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si8210_a","class":"TODO::Senthil","roles":{"answer":{"title":"The mAb binds to antigens on the surface of tumour cells and mark the cell for destruction by the immune system.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si8221","class":"TODO::Senthil","title":" ","roles":{"textData":{}}},{"id":"si8225","class":"TODO::Senthil","title":"The mAb binds to specific molecules or receptors on the surface of cancer cells and directly initiates programmed cell death. ","roles":{"textData":{}}},{"id":"si8225","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si8221_a","class":"TODO::Senthil","roles":{"answer":{"title":"The mAb binds to specific molecules or receptors on the surface of cancer cells and directly initiates programmed cell death.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si8596","class":"TODO::Senthil","title":" ","roles":{"textData":{}}},{"id":"si8600","class":"TODO::Senthil","title":"The mAb binds to signal receptors on the surface of tumour cells or immune cells and blocks immunosuppressive pathways. ","roles":{"textData":{}}},{"id":"si8600","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si8596_a","class":"TODO::Senthil","roles":{"answer":{"title":"The mAb binds to signal receptors on the surface of tumour cells or immune cells and blocks immunosuppressive pathways.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si8611","class":"TODO::Senthil","title":" ","roles":{"textData":{}}},{"id":"si8615","class":"TODO::Senthil","title":"The mAb binds to specific molecules or receptors on the surface of cancer and interrupts normal cellular processes, leading to cell death. ","roles":{"textData":{}}},{"id":"si8615","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si8611_a","class":"TODO::Senthil","roles":{"answer":{"title":"The mAb binds to specific molecules or receptors on the surface of cancer and interrupts normal cellular processes, leading to cell death.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si8360","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide8115q0","for":"Slide8115q0"},"textData":{}}},{"id":"si8377","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide8115q0","for":"Slide8115q0"},"textData":{}}},{"id":"si8390","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide8115q0","for":"Slide8115q0"},"textData":{}}},{"id":"si8229","class":"TODO::Senthil","title":"That’s right!   mAbs which rely on involvement of the immune system or interrupt normal immune pathways in order damage or destroy cancer cells are termed immunotherapies. Targeted therapies are able to directly destroy cancer cells. They do not require involvement of the immune system.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"textData":{}}},{"id":"si8242","class":"TODO::Senthil","title":"Almost!   mAbs which rely on involvement of the immune system or interruption of normal immune pathways in order damage or destroy cancer cells are termed immunotherapies. Targeted therapies are able to directly destroy cancer cells. They do not require involvement of the immune system. You may wish to revise topic 1, module 2: monoclonal antibodies  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"textData":{}}},{"id":"si8255","class":"TODO::Senthil","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide8115q0"},"textData":{}}},{"id":"Slide8115","class":"Question Slide","instance":"","thumbnail":"","children":["si15431","si15523","SmartShape_8","si8195","si8214","si8225","si8600","si8615","si8360","si8377","si8390","si8255"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide8115"},"question":{"interactionId":"8182","quizId":377,"title":"Multiple Choice","text":"mAbs may be used as an immunotherapy or as a targeted therapy in the treatment of cancer. Which of the following is true about the use of mAbs as an immunotherapy? (select all that apply)\r\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":true,"correctAnswers":["1","3"],"score":{"weight":10,"penalty":0}}}},{"id":"si15435","class":"TODO::Senthil","roles":{}},{"id":"si15541","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide11080q1"},"textData":{}}},{"id":"SmartShape_14","class":"TODO::Senthil","instance":"SmartShape_14","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide11080q1"},"textData":{}}},{"id":"si11218","class":"TODO::Senthil","roles":{}},{"id":"si11154","class":"TODO::Senthil","title":"Antibody dependant cellular cytotoxicity (ADCC) is an immune mediated mechanism of action that some mAbs such as Rituximab and Cetuximab use in order to flag tumour cells for destruction by the immune system.   Can you correctly arrange the steps in ADCC below? ","roles":{"textData":{}}},{"id":"si11170","class":"TODO::Senthil","title":"1. ","roles":{"textData":{}}},{"id":"si11174","class":"TODO::Senthil","roles":{}},{"id":"si11174c","class":"TODO::Senthil","roles":{"answer":{"title":"The mAb binds to target antigens on the surface of tumour cells. ","index":"Not implemented"}}},{"id":"si11180","class":"TODO::Senthil","title":"2. ","roles":{"textData":{}}},{"id":"si11184","class":"TODO::Senthil","roles":{}},{"id":"si11184c","class":"TODO::Senthil","roles":{"answer":{"title":"Passing immune cells which express Fc receptors on their cell surface recognise the Fc region of the antibody and bind to it.","index":"Not implemented"}}},{"id":"si11382","class":"TODO::Senthil","title":"3. ","roles":{"textData":{}}},{"id":"si11386","class":"TODO::Senthil","roles":{}},{"id":"si11386c","class":"TODO::Senthil","roles":{"answer":{"title":"The immune cell is now activated. ","index":"Not implemented"}}},{"id":"si15657","class":"TODO::Senthil","title":"4. ","roles":{"textData":{}}},{"id":"si15661","class":"TODO::Senthil","roles":{}},{"id":"si15661c","class":"TODO::Senthil","roles":{"answer":{"title":"The activated immune cell destroys the bound cancer cell.","index":"Not implemented"}}},{"id":"si11306","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide11080q1","for":"Slide11080q1"},"textData":{}}},{"id":"si11323","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide11080q1","for":"Slide11080q1"},"textData":{}}},{"id":"si11336","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide11080q1","for":"Slide11080q1"},"textData":{}}},{"id":"si11188","class":"TODO::Senthil","title":"That’s correct.   ADCC typically involves the binding and activation of natural killer cells (NK cells), however macrophages and neutrophils may also play a role.   Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide11080q1"},"textData":{}}},{"id":"si16695","class":"TODO::Senthil","title":"Not quite.   ADCC involves: The mAb binds to target antigens on the surface of tumour cells.  Passing immune cells which express Fc receptors on their cell surface recognise the Fc region of the antibody and bind to it. The immune cell is now activated  The activated immune cell destroys the bound cancer cell.  You may wish to review topic 1 of module 2: monoclonal antibodies  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide11080q1"},"textData":{}}},{"id":"Slide11080","class":"Question Slide","instance":"","thumbnail":"","children":["si15435","si15541","SmartShape_14","si11154","si11174","si11184","si11386","si15661","si11306","si11323","si11336"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide11080"},"question":{"interactionId":"11147","quizId":377,"title":"Sequence","text":"Antibody dependant cellular cytotoxicity (ADCC) is an immune mediated mechanism of action that some mAbs such as Rituximab and Cetuximab use in order to flag tumour cells for destruction by the immune system. \r\rCan you correctly arrange the steps in ADCC below?\r","type":"graded","ikc":false,"interactionType":"sequencing","ramdomized":false,"correctAnswers":["si11174c","si11184c","si11386c","si15661c"],"score":{"weight":10,"penalty":0}}}},{"id":"si15443","class":"TODO::Senthil","roles":{}},{"id":"si15577","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"textData":{}}},{"id":"SmartShape_40","class":"TODO::Senthil","instance":"SmartShape_40","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"textData":{}}},{"id":"si14873","class":"TODO::Senthil","instance":"Text_Caption_122","roles":{}},{"id":"si14749","class":"TODO::Senthil","instance":"Text_Caption_112","title":"Which of the following statement is TRUE? (select all that apply) ","roles":{"textData":{}}},{"id":"si14760","class":"TODO::Senthil","instance":"Text_Caption_113","title":" ","roles":{"textData":{}}},{"id":"si14764","class":"TODO::Senthil","instance":"Text_Caption_114","title":"Immune checkpoint inhibitors are a subset of monoclonal antibodies whose mechanism of action involves interrupting immunosuppressive pathways. ","roles":{"textData":{}}},{"id":"si14764","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si14760_a","class":"TODO::Senthil","roles":{"answer":{"title":"Immune checkpoint inhibitors are a subset of monoclonal antibodies whose mechanism of action involves interrupting immunosuppressive pathways.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si14771","class":"TODO::Senthil","instance":"Text_Caption_115","title":" ","roles":{"textData":{}}},{"id":"si14775","class":"TODO::Senthil","instance":"Text_Caption_116","title":"mAbs may activate the complement system in order to destroy tumour cells as one of their mechanisms of action. ","roles":{"textData":{}}},{"id":"si14775","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si14771_a","class":"TODO::Senthil","roles":{"answer":{"title":"mAbs may activate the complement system in order to destroy tumour cells as one of their mechanisms of action.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si14782","class":"TODO::Senthil","instance":"Text_Caption_117","title":" ","roles":{"textData":{}}},{"id":"si14786","class":"TODO::Senthil","instance":"Text_Caption_118","title":"Monoclonal antibodies consist of two regions, a Fab region which attracts and binds immune cells and an FC region which seeks and binds to matching antigens. ","roles":{"textData":{}}},{"id":"si14786","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si14782_a","class":"TODO::Senthil","roles":{"answer":{"title":"Monoclonal antibodies consist of two regions, a Fab region which attracts and binds immune cells and an FC region which seeks and binds to matching antigens.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si14793","class":"TODO::Senthil","instance":"Text_Caption_119","title":" ","roles":{"textData":{}}},{"id":"si14797","class":"TODO::Senthil","instance":"Text_Caption_120","title":"Monoclonal antibodies consist of two regions, a Fab region which seeks and binds to matching antigens and an FC region which attracts and binds immune cells. ","roles":{"textData":{}}},{"id":"si14797","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si14793_a","class":"TODO::Senthil","roles":{"answer":{"title":"Monoclonal antibodies consist of two regions, a Fab region which seeks and binds to matching antigens and an FC region which attracts and binds immune cells.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si14945","class":"TODO::Senthil","instance":"Button_27","title":" ","roles":{"click":{"subtype":"reviewModeBack","question":"Slide15079q2","for":"Slide15079q2"},"textData":{}}},{"id":"si14957","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"reviewModeBack","question":"Slide15079q2","for":"Slide15079q2"},"textData":{}}},{"id":"si14969","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"reviewModeBack","question":"Slide15079q2","for":"Slide15079q2"},"textData":{}}},{"id":"si14999","class":"TODO::Senthil","instance":"Button_28","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide15079q2","for":"Slide15079q2"},"textData":{}}},{"id":"si15011","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide15079q2","for":"Slide15079q2"},"textData":{}}},{"id":"si15023","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide15079q2","for":"Slide15079q2"},"textData":{}}},{"id":"si14823","class":"TODO::Senthil","instance":"SmartShape_41","title":"Well done!  Immune checkpoints are an important subset of monoclonal antibodies whose clinical use is growing rapidly.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"textData":{}}},{"id":"si14842","class":"TODO::Senthil","instance":"SmartShape_42","title":"Not quite.   Monoclonal antibodies consist of a Fab region, which makes up the twin prongs of the Y shape of the antibody and an Fc region which makes up the base of the Y. The fab region binds antibodies and the Fc region which attracts and binds immune cells. Immune checkpoints are an important subset of monoclonal antibodies whose clinical use is growing rapidly.   You may wish to review topic 1 of module 2: monoclonal antibodies.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"textData":{}}},{"id":"si14861","class":"TODO::Senthil","instance":"SmartShape_43","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide15079q2"},"textData":{}}},{"id":"Slide15079","class":"Question Slide","instance":"","thumbnail":"","children":["si15443","si15577","SmartShape_40","si14749","si14764","si14775","si14786","si14797","si14945","si14957","si14969","si14999","si15011","si15023","si14861"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide15079"},"question":{"interactionId":"14705","quizId":377,"title":"Multiple Choice","text":"Which of the following statement is TRUE? (select all that apply)\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":true,"correctAnswers":["1","2","4"],"score":{"weight":10,"penalty":0}}}},{"id":"si15433","class":"TODO::Senthil","roles":{}},{"id":"si15532","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"textData":{}}},{"id":"SmartShape_12","class":"TODO::Senthil","instance":"SmartShape_12","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"textData":{}}},{"id":"si10810","class":"TODO::Senthil","instance":"Text_Caption_28","roles":{}},{"id":"si10692","class":"TODO::Senthil","instance":"Text_Caption_19","title":"Which of the following correctly describe immune checkpoint pathways?  (select all that apply) ","roles":{"textData":{}}},{"id":"si10703","class":"TODO::Senthil","instance":"Text_Caption_20","title":" ","roles":{"textData":{}}},{"id":"si10707","class":"TODO::Senthil","instance":"Text_Caption_21","title":"Immune checkpoint pathways are a natural immune regulatory process which under normal conditions prevents an overactive immune response. ","roles":{"textData":{}}},{"id":"si10707","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si10703_a","class":"TODO::Senthil","roles":{"answer":{"title":"Immune checkpoint pathways are a natural immune regulatory process which under normal conditions prevents an overactive immune response.\r","index":"Not implemented","score":{"weight":10}}}},{"id":"si10714","class":"TODO::Senthil","instance":"Text_Caption_22","title":" ","roles":{"textData":{}}},{"id":"si10718","class":"TODO::Senthil","instance":"Text_Caption_23","title":"Immune checkpoints pathways involve extracellular signalling which supresses immune activity. ","roles":{"textData":{}}},{"id":"si10718","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si10714_a","class":"TODO::Senthil","roles":{"answer":{"title":"Immune checkpoints pathways involve extracellular signalling which supresses immune activity.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si10725","class":"TODO::Senthil","instance":"Text_Caption_24","title":" ","roles":{"textData":{}}},{"id":"si10729","class":"TODO::Senthil","instance":"Text_Caption_25","title":"Immune checkpoint pathways involve activation of co-inhibitory molecules which may be present on the surface of normal cells, tumour cells or immune cells. ","roles":{"textData":{}}},{"id":"si10729","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si10725_a","class":"TODO::Senthil","roles":{"answer":{"title":"Immune checkpoint pathways involve activation of co-inhibitory molecules which may be present on the surface of normal cells, tumour cells or immune cells.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si10736","class":"TODO::Senthil","instance":"Text_Caption_26","title":" ","roles":{"textData":{}}},{"id":"si10740","class":"TODO::Senthil","instance":"Text_Caption_27","title":"Immune checkpoint pathways turn up the immune response by activating T cells and improve their function. ","roles":{"textData":{}}},{"id":"si10740","class":"TODO::Senthil","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si10736_a","class":"TODO::Senthil","roles":{"answer":{"title":"Immune checkpoint pathways turn up the immune response by activating T cells and improve their function.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si10936","class":"TODO::Senthil","instance":"Button_6","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide11016q3","for":"Slide11016q3"},"textData":{}}},{"id":"si10948","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide11016q3","for":"Slide11016q3"},"textData":{}}},{"id":"si10960","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide11016q3","for":"Slide11016q3"},"textData":{}}},{"id":"si10766","class":"TODO::Senthil","instance":"SmartShape_6","title":"Well done!  Immune checkpoint pathways turn down the immune response by deactivating T-cells and supressing their function.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"textData":{}}},{"id":"si10785","class":"TODO::Senthil","instance":"SmartShape_7","title":"Not quite.   Immune checkpoint pathways are natural immune regulatory pathways which under normal conditions prevent an overactive immune response. Immune checkpoints involve activation of co-inhibitory modules which may be present on normal cells, tumour cells or immune cells. Activation of these molecules creates an immunosuppressive extracellular signal which turns down the immune response, deactivating T cells and suppressive their function.   You may wish to review module 2, topic 2: immune checkpoint inhibitors  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"textData":{}}},{"id":"si10804","class":"TODO::Senthil","instance":"SmartShape_13","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide11016q3"},"textData":{}}},{"id":"Slide11016","class":"Question Slide","instance":"","thumbnail":"","children":["si15433","si15532","SmartShape_12","si10692","si10707","si10718","si10729","si10740","si10936","si10948","si10960","si10804"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide11016"},"question":{"interactionId":"10642","quizId":377,"title":"Multiple Choice","text":"Which of the following correctly describe immune checkpoint pathways? \r(select all that apply)\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":true,"correctAnswers":["1","2","3"],"score":{"weight":10,"penalty":0}}}},{"id":"si16062","class":"TODO::Senthil","roles":{}},{"id":"si16104","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"textData":{}}},{"id":"SmartShape_45","class":"TODO::Senthil","instance":"SmartShape_45","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"textData":{}}},{"id":"si15855","class":"TODO::Senthil","instance":"Text_Caption_133","roles":{}},{"id":"si15737","class":"TODO::Senthil","instance":"Text_Caption_124","title":"Activation of immune checkpoint pathways supress immune activity. Tumour cells have developed mechanisms to activate these pathways in order to avoid immune detection.  Which of the following represent ways that tumour cells may increase the activation of immune checkpoint pathways to subvert the immune system? (select all that apply) ","roles":{"textData":{}}},{"id":"si15748","class":"TODO::Senthil","instance":"Text_Caption_125","title":" ","roles":{"textData":{}}},{"id":"si15752","class":"TODO::Senthil","instance":"Text_Caption_126","title":"Increasing the amount of co-inhibitory molecules on their cell surface, e.g. PD-L1 ","roles":{"textData":{}}},{"id":"si15752","class":"TODO::Senthil","instance":"68","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si15748_a","class":"TODO::Senthil","instance":"67","roles":{"answer":{"title":"Increasing the amount of co-inhibitory molecules on their cell surface, e.g. PD-L1\r","index":"Not implemented","score":{"weight":10}}}},{"id":"si15759","class":"TODO::Senthil","instance":"Text_Caption_127","title":" ","roles":{"textData":{}}},{"id":"si15763","class":"TODO::Senthil","instance":"Text_Caption_128","title":"Increasing the amount of co-stimulatory molecules on their surface, e.g. CD28 ","roles":{"textData":{}}},{"id":"si15763","class":"TODO::Senthil","instance":"70","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si15759_a","class":"TODO::Senthil","instance":"69","roles":{"answer":{"title":"Increasing the amount of co-stimulatory molecules on their surface, e.g. CD28\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si15770","class":"TODO::Senthil","instance":"Text_Caption_129","title":" ","roles":{"textData":{}}},{"id":"si15774","class":"TODO::Senthil","instance":"Text_Caption_130","title":"Increasing the amount of tumour antigens they express on their cell surface. ","roles":{"textData":{}}},{"id":"si15774","class":"TODO::Senthil","instance":"72","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si15770_a","class":"TODO::Senthil","instance":"71","roles":{"answer":{"title":"Increasing the amount of tumour antigens they express on their cell surface.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si15781","class":"TODO::Senthil","instance":"Text_Caption_131","title":" ","roles":{"textData":{}}},{"id":"si15785","class":"TODO::Senthil","instance":"Text_Caption_132","title":"Stimulating T cells to express more inhibitory molecules on their surface, e.g. PD-1 ","roles":{"textData":{}}},{"id":"si15785","class":"TODO::Senthil","instance":"74","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si15781_a","class":"TODO::Senthil","instance":"73","roles":{"answer":{"title":"Stimulating T cells to express more inhibitory molecules on their surface, e.g. PD-1\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si15981","class":"TODO::Senthil","instance":"Button_32","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide16061q4","for":"Slide16061q4"},"textData":{}}},{"id":"si15993","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide16061q4","for":"Slide16061q4"},"textData":{}}},{"id":"si16005","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide16061q4","for":"Slide16061q4"},"textData":{}}},{"id":"si15811","class":"TODO::Senthil","instance":"SmartShape_46","title":"That’s right!   Tumour cells may increase the activation of immune checkpoint pathways by increasing the amount of co-inhibitory molecules on their cell surface or stimulating T cells to increase more co-inhibitory molecules on their surface.   Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"textData":{}}},{"id":"si15830","class":"TODO::Senthil","instance":"SmartShape_47","title":"Almost!   Tumour cells may increase the activation of immune checkpoint pathways by increasing the amount of co-inhibitory molecules on their cell surface or stimulating T cells to increase more co-inhibitory molecules on their surface.   You may wish to review module 2, topic 2: immune checkpoint inhibitors.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"textData":{}}},{"id":"si15849","class":"TODO::Senthil","instance":"SmartShape_48","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide16061q4"},"textData":{}}},{"id":"Slide16061","class":"Question Slide","instance":"","thumbnail":"","children":["si16062","si16104","SmartShape_45","si15737","si15752","si15763","si15774","si15785","si15981","si15993","si16005","si15849"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide16061"},"question":{"interactionId":"15687","quizId":377,"title":"Multiple Choice","text":"Activation of immune checkpoint pathways supress immune activity. Tumour cells have developed mechanisms to activate these pathways in order to avoid immune detection.\r\rWhich of the following represent ways that tumour cells may increase the activation of immune checkpoint pathways to subvert the immune system?\r(select all that apply)\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":true,"correctAnswers":["1","4"],"score":{"weight":10,"penalty":0}}}},{"id":"si15451","class":"TODO::Senthil","roles":{}},{"id":"si15615","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide9659q5"},"textData":{}}},{"id":"SmartShape_10","class":"TODO::Senthil","instance":"SmartShape_10","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide9659q5"},"textData":{}}},{"id":"SmartShape_53","class":"TODO::Senthil","instance":"SmartShape_53","title":" ","roles":{"click":{"subtype":"button","question":"Slide9659q5"},"textData":{}}},{"id":"si9891","class":"TODO::Senthil","roles":{}},{"id":"si9756","class":"TODO::Senthil","title":"Two prominent immune checkpoints in tumour immunology are CTLA4 and PD-1. Please select the correct checkpoint for each of the following statements about PD-1 and CTLA4. ","roles":{"textData":{}}},{"id":"si9787","class":"TODO::Senthil","title":"1. ","roles":{"textData":{}}},{"id":"si9791","class":"TODO::Senthil","title":"Expression on the surface of  T cells is increased during the effector (antigen neutralisation) phase. ","roles":{"textData":{}}},{"id":"si9808","class":"TODO::Senthil","title":"1. ","roles":{"textData":{}}},{"id":"si9812","class":"TODO::Senthil","title":"When interacts with PD-L1 results in the suppression of    T cell activity. ","roles":{"textData":{}}},{"id":"si9829","class":"TODO::Senthil","title":"1. ","roles":{"textData":{}}},{"id":"si9833","class":"TODO::Senthil","title":"Tumours can stimulate T cells to increase the expression of this molecule on their surface.  ","roles":{"textData":{}}},{"id":"si16122","class":"TODO::Senthil","title":"2. ","roles":{"textData":{}}},{"id":"si16126","class":"TODO::Senthil","title":"Expression on the surface of T cells is increased during the priming (antigen recognition) phase. ","roles":{"textData":{}}},{"id":"si16158","class":"TODO::Senthil","title":"2. ","roles":{"textData":{}}},{"id":"si16162","class":"TODO::Senthil","title":"When interacts with CD80/86 on the surface of other cells contributes to T cell deactivation. ","roles":{"textData":{}}},{"id":"si16140","class":"TODO::Senthil","title":"2. ","roles":{"textData":{}}},{"id":"si16144","class":"TODO::Senthil","title":"When interacts with CD28 on the surface of other cells, contributes to stimulation of T cell activity.  ","roles":{"textData":{}}},{"id":"si9797","class":"TODO::Senthil","title":"1. ","roles":{"textData":{}}},{"id":"si9801","class":"TODO::Senthil","title":"PD1 ","roles":{"textData":{}}},{"id":"si9801ans","class":"TODO::Senthil","roles":{"answer":{"title":"PD1","index":"Not implemented"}}},{"id":"si9818","class":"TODO::Senthil","title":"2. ","roles":{"textData":{}}},{"id":"si9822","class":"TODO::Senthil","title":"CTLA4 ","roles":{"textData":{}}},{"id":"si9822ans","class":"TODO::Senthil","roles":{"answer":{"title":"CTLA4","index":"Not implemented"}}},{"id":"si9979","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide9659q5","for":"Slide9659q5"},"textData":{}}},{"id":"si9996","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide9659q5","for":"Slide9659q5"},"textData":{}}},{"id":"si10009","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide9659q5","for":"Slide9659q5"},"textData":{}}},{"id":"si16167","class":"TODO::Senthil","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide9659q5"},"textData":{}}},{"id":"si16180","class":"TODO::Senthil","title":"Not quite.   PD-1 and CTLA4 are both expressed on the surface of activated T cells and both contribute to the deactivation of  T cells but there are some differences between each.  PD-1 expression is increased during the effector phase and when paired with PD-L1, often upregulated on the surface of tumour cells, results in suppression of  T cell activity, improving tumour survival.  CTLA4 expression is increased during the priming phase. When paired with CD80/86 on the surface of tumour cells it results in T cell deactivation before the T cell can enter the effector phase and become capable of destroying cancer cells.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide9659q5"},"textData":{}}},{"id":"si16193","class":"TODO::Senthil","title":"Well done!   PD-1 and CTLA4 are expressed on the surface of activated T cells and may both contribute to the deactivation of  T cells in the tumour microenvironment, improving tumour survival.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide9659q5"},"textData":{}}},{"id":"Slide9659","class":"Question Slide","instance":"","thumbnail":"","children":["si15451","si15615","SmartShape_10","SmartShape_53","si9756","si9801","si9822","si9979","si9996","si10009","si16167"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide9659"},"question":{"interactionId":"9726","quizId":377,"title":"Matching","text":"Two prominent immune checkpoints in tumour immunology are CTLA4 and PD-1. Please select the correct checkpoint for each of the following statements about PD-1 and CTLA4.\r","type":"graded","ikc":false,"interactionType":"matching","ramdomized":true,"correctAnswers":[],"score":{"weight":10,"penalty":0}}}},{"id":"si15437","class":"TODO::Senthil","roles":{}},{"id":"si15550","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide12297q6"},"textData":{}}},{"id":"SmartShape_19","class":"TODO::Senthil","instance":"SmartShape_19","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide12297q6"},"textData":{}}},{"id":"si12091","class":"TODO::Senthil","instance":"Text_Caption_64","roles":{}},{"id":"si11973","class":"TODO::Senthil","instance":"Text_Caption_55","title":"Immune checkpoint inhibitors (ICIs) are a subset of monoclonal antibodies which play a role in inhibiting or disrupting those signalling pathways that suppress immune activity.  How do ICIs block immunosuppressive pathways?  ","roles":{"textData":{}}},{"id":"si11984","class":"TODO::Senthil","instance":"Text_Caption_56","title":" ","roles":{"textData":{}}},{"id":"si11988","class":"TODO::Senthil","instance":"Text_Caption_57","title":"ICIs bind to antigens on the surface of tumour cells and flag the cell for destruction by the immune system. ","roles":{"textData":{}}},{"id":"si11984_a","class":"TODO::Senthil","roles":{"answer":{"title":"ICIs bind to antigens on the surface of tumour cells and flag the cell for destruction by the immune system.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si11995","class":"TODO::Senthil","instance":"Text_Caption_58","title":" ","roles":{"textData":{}}},{"id":"si11999","class":"TODO::Senthil","instance":"Text_Caption_59","title":"ICIs bind to the cell surface receptors, ligands or molecules involved in immune checkpoints, blocking signalling and preventing completion of the immunosuppressive pathway. ","roles":{"textData":{}}},{"id":"si11995_a","class":"TODO::Senthil","roles":{"answer":{"title":"ICIs bind to the cell surface receptors, ligands or molecules involved in immune checkpoints, blocking signalling and preventing completion of the immunosuppressive pathway.\r","index":"Not implemented","score":{"weight":10}}}},{"id":"si12006","class":"TODO::Senthil","instance":"Text_Caption_60","title":" ","roles":{"textData":{}}},{"id":"si12010","class":"TODO::Senthil","instance":"Text_Caption_61","title":"ICIs activate the complementary pathway, leading to tumour cell destruction. ","roles":{"textData":{}}},{"id":"si12006_a","class":"TODO::Senthil","roles":{"answer":{"title":"ICIs activate the complementary pathway, leading to tumour cell destruction.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si12017","class":"TODO::Senthil","instance":"Text_Caption_62","title":" ","roles":{"textData":{}}},{"id":"si12021","class":"TODO::Senthil","instance":"Text_Caption_63","title":"ICIs recruit other immune cells to the tumour microenvironment which then attack the tumour cells. ","roles":{"textData":{}}},{"id":"si12017_a","class":"TODO::Senthil","roles":{"answer":{"title":"ICIs recruit other immune cells to the tumour microenvironment which then attack the tumour cells.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si12217","class":"TODO::Senthil","instance":"Button_13","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide12297q6","for":"Slide12297q6"},"textData":{}}},{"id":"si12229","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide12297q6","for":"Slide12297q6"},"textData":{}}},{"id":"si12241","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide12297q6","for":"Slide12297q6"},"textData":{}}},{"id":"si12047","class":"TODO::Senthil","instance":"SmartShape_20","title":"Well done!  ICIs block immunosuppressive pathways by binding to the cell surface receptors, ligands or molecules involved in immune checkpoints, blocking signalling and preventing completion of the immunosuppressive pathway.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide12297q6"},"textData":{}}},{"id":"si12066","class":"TODO::Senthil","instance":"SmartShape_21","title":"Not quite.   ICIs block immunosuppressive pathways by binding to the cell surface receptors, ligands or molecules involved in immune checkpoints, blocking signalling and preventing completion of the immunosuppressive pathway.   You may wish to revisit module 2, topic 2: Immune checkpoint inhibitors  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide12297q6"},"textData":{}}},{"id":"si12085","class":"TODO::Senthil","instance":"SmartShape_22","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide12297q6"},"textData":{}}},{"id":"Slide12297","class":"Question Slide","instance":"","thumbnail":"","children":["si15437","si15550","SmartShape_19","si11973","si11988","si11999","si12010","si12021","si12217","si12229","si12241","si12085"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide12297"},"question":{"interactionId":"11923","quizId":377,"title":"Multiple Choice","text":"Immune checkpoint inhibitors (ICIs) are a subset of monoclonal antibodies which play a role in inhibiting or disrupting those signalling pathways that suppress immune activity.\r\rHow do ICIs block immunosuppressive pathways? \r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":true,"correctAnswers":["2"],"score":{"weight":10,"penalty":0}}}},{"id":"si15439","class":"TODO::Senthil","roles":{}},{"id":"si15559","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"textData":{}}},{"id":"SmartShape_25","class":"TODO::Senthil","instance":"SmartShape_25","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"textData":{}}},{"id":"si13107","class":"TODO::Senthil","instance":"Text_Caption_96","roles":{}},{"id":"si12967","class":"TODO::Senthil","instance":"Text_Caption_83","title":"Which of the following drugs are immune checkpoint inhibitors? (select all that apply) ","roles":{"textData":{}}},{"id":"si12978","class":"TODO::Senthil","instance":"Text_Caption_84","title":" ","roles":{"textData":{}}},{"id":"si12982","class":"TODO::Senthil","instance":"Text_Caption_85","title":"Nivolumab is a mAb that targets and binds to PD-1 on T cells, preventing interaction with PD-L1 on cancer cells. ","roles":{"textData":{}}},{"id":"si12982","class":"TODO::Senthil","instance":"30_37","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si12978_a","class":"TODO::Senthil","instance":"29_36","roles":{"answer":{"title":"Nivolumab is a mAb that targets and binds to PD-1 on T cells, preventing interaction with PD-L1 on cancer cells.\r","index":"Not implemented","score":{"weight":10}}}},{"id":"si12989","class":"TODO::Senthil","instance":"Text_Caption_86","title":" ","roles":{"textData":{}}},{"id":"si12993","class":"TODO::Senthil","instance":"Text_Caption_87","title":"Ipilimumab is a mAb that targets and binds to CTLA4 on T cells, preventing interaction with CD80/86 on cancer cells. ","roles":{"textData":{}}},{"id":"si12993","class":"TODO::Senthil","instance":"32_38","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si12989_a","class":"TODO::Senthil","instance":"31_37","roles":{"answer":{"title":"Ipilimumab is a mAb that targets and binds to CTLA4 on T cells, preventing interaction with CD80/86 on cancer cells.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13022","class":"TODO::Senthil","instance":"Text_Caption_92","title":" ","roles":{"textData":{}}},{"id":"si13026","class":"TODO::Senthil","instance":"Text_Caption_93","title":"Atezolizumab is a mAb that targets and binds to PD-L1 which may be found on the surface of tumour cells and blocks the interaction of this ligand with PD-1 on T cells. ","roles":{"textData":{}}},{"id":"si13026","class":"TODO::Senthil","instance":"51","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si13022_a","class":"TODO::Senthil","instance":"50","roles":{"answer":{"title":"Atezolizumab is a mAb that targets and binds to PD-L1 which may be found on the surface of tumour cells and blocks the interaction of this ligand with PD-1 on T cells.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13033","class":"TODO::Senthil","instance":"Text_Caption_94","title":" ","roles":{"textData":{}}},{"id":"si13037","class":"TODO::Senthil","instance":"Text_Caption_95","title":"Rituximab is a mAb that targets and binds to the CD20 antigen on B lymphocytes and recruits immune cells to destroy the bound B cell. ","roles":{"textData":{}}},{"id":"si13037","class":"TODO::Senthil","instance":"53","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si13033_a","class":"TODO::Senthil","instance":"52","roles":{"answer":{"title":"Rituximab is a mAb that targets and binds to the CD20 antigen on B lymphocytes and recruits immune cells to destroy the bound B cell.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13233","class":"TODO::Senthil","instance":"Button_20","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide13313q7","for":"Slide13313q7"},"textData":{}}},{"id":"si13245","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide13313q7","for":"Slide13313q7"},"textData":{}}},{"id":"si13257","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide13313q7","for":"Slide13313q7"},"textData":{}}},{"id":"si13063","class":"TODO::Senthil","instance":"SmartShape_27","title":"Well done!  Immune checkpoint inhibitors are those mAbs that block co-inhibitory molecules in order to prevent immunosuppressive pathways being initiated.   Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"textData":{}}},{"id":"si13082","class":"TODO::Senthil","instance":"SmartShape_28","title":"Not quite.   Immune checkpoint inhibitors are those mAbs that block co-inhibitory molecules in order to prevent immunosuppressive pathways being initiated. Nivolumab, Ipilimumab and Atezolizumab are all immune checkpoint inhibitors. Rituximab destroys cancer cells via ADCC.   You may wish to review module 2, topic 2: Immune checkpoint inhibitors  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"textData":{}}},{"id":"si13101","class":"TODO::Senthil","instance":"SmartShape_29","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide13313q7"},"textData":{}}},{"id":"Slide13313","class":"Question Slide","instance":"","thumbnail":"","children":["si15439","si15559","SmartShape_25","si12967","si12982","si12993","si13026","si13037","si13233","si13245","si13257","si13101"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide13313"},"question":{"interactionId":"12917","quizId":377,"title":"Multiple Choice","text":"Which of the following drugs are immune checkpoint inhibitors? (select all that apply)\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":true,"correctAnswers":["1","3","2"],"score":{"weight":10,"penalty":0}}}},{"id":"si16621","class":"TODO::Senthil","roles":{}},{"id":"si16663","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide16620q8"},"textData":{}}},{"id":"SmartShape_49","class":"TODO::Senthil","instance":"SmartShape_49","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide16620q8"},"textData":{}}},{"id":"si16414","class":"TODO::Senthil","instance":"Text_Caption_144","roles":{}},{"id":"si16296","class":"TODO::Senthil","instance":"Text_Caption_135","title":"Which of the below best describes the mechanism of action of therapeutic cancer vaccines? ","roles":{"textData":{}}},{"id":"si16307","class":"TODO::Senthil","instance":"Text_Caption_136","title":" ","roles":{"textData":{}}},{"id":"si16311","class":"TODO::Senthil","instance":"Text_Caption_137","title":"Therapeutic cancer vaccines prevent cancer caused by viruses such as HPV. ","roles":{"textData":{}}},{"id":"si16307_a","class":"TODO::Senthil","roles":{"answer":{"title":"Therapeutic cancer vaccines prevent cancer caused by viruses such as HPV.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si16318","class":"TODO::Senthil","instance":"Text_Caption_138","title":" ","roles":{"textData":{}}},{"id":"si16322","class":"TODO::Senthil","instance":"Text_Caption_139","title":"Therapeutic cancer vaccines reduce the amount of tumour antigens on the surface of tumour cells, improving the immune system’s ability to recognise the cancer. ","roles":{"textData":{}}},{"id":"si16318_a","class":"TODO::Senthil","roles":{"answer":{"title":"Therapeutic cancer vaccines reduce the amount of tumour antigens on the surface of tumour cells, improving the immune system’s ability to recognise the cancer.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si16329","class":"TODO::Senthil","instance":"Text_Caption_140","title":" ","roles":{"textData":{}}},{"id":"si16333","class":"TODO::Senthil","instance":"Text_Caption_141","title":"Therapeutic cancer vaccines introduce tumour antigens into the body, improving tumour antigen presentation and improving the ability of the adaptive immune system to recognise and fight the cancer cells. ","roles":{"textData":{}}},{"id":"si16329_a","class":"TODO::Senthil","roles":{"answer":{"title":"Therapeutic cancer vaccines introduce tumour antigens into the body, improving tumour antigen presentation and improving the ability of the adaptive immune system to recognise and fight the cancer cells.\r","index":"Not implemented","score":{"weight":10}}}},{"id":"si16340","class":"TODO::Senthil","instance":"Text_Caption_142","title":" ","roles":{"textData":{}}},{"id":"si16344","class":"TODO::Senthil","instance":"Text_Caption_143","title":"Therapeutic cancer vaccines introduce extra immune cells into the body, meaning there are more immune cells available to attack the cancer. ","roles":{"textData":{}}},{"id":"si16340_a","class":"TODO::Senthil","roles":{"answer":{"title":"Therapeutic cancer vaccines introduce extra immune cells into the body, meaning there are more immune cells available to attack the cancer.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si16540","class":"TODO::Senthil","instance":"Button_36","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide16620q8","for":"Slide16620q8"},"textData":{}}},{"id":"si16552","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide16620q8","for":"Slide16620q8"},"textData":{}}},{"id":"si16564","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide16620q8","for":"Slide16620q8"},"textData":{}}},{"id":"si16370","class":"TODO::Senthil","instance":"SmartShape_50","title":"Well done!  Therapeutic cancer vaccines introduce tumour antigens into the body, improving tumour antigen presentation and improving the ability of the adaptive immune system to recognise and fight the cancer cells. The cervical cancer vaccine is a preventative cancer vaccine, not a therapeutic cancer vaccine.   Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide16620q8"},"textData":{}}},{"id":"si16389","class":"TODO::Senthil","instance":"SmartShape_51","title":"Not quite.   Therapeutic cancer vaccines introduce tumour antigens into the body, improving tumour antigen presentation and improving the ability of the adaptive immune system to recognise and fight the cancer cells. The cervical cancer vaccine is a preventative cancer vaccine, not a therapeutic cancer vaccine.   You may wish to revise module 2, topic 3: cancer vaccines  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide16620q8"},"textData":{}}},{"id":"si16408","class":"TODO::Senthil","instance":"SmartShape_52","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide16620q8"},"textData":{}}},{"id":"Slide16620","class":"Question Slide","instance":"","thumbnail":"","children":["si16621","si16663","SmartShape_49","si16296","si16311","si16322","si16333","si16344","si16540","si16552","si16564","si16408"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide16620"},"question":{"interactionId":"16246","quizId":377,"title":"Multiple Choice","text":"Which of the below best describes the mechanism of action of therapeutic cancer vaccines?\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":false,"correctAnswers":["2"],"score":{"weight":10,"penalty":0}}}},{"id":"si15441","class":"TODO::Senthil","roles":{}},{"id":"si15568","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"textData":{}}},{"id":"SmartShape_30","class":"TODO::Senthil","instance":"SmartShape_30","title":"Principles of Immunotherapy ","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"textData":{}}},{"id":"si13600","class":"TODO::Senthil","instance":"Text_Caption_111","roles":{}},{"id":"si13460","class":"TODO::Senthil","instance":"Text_Caption_98","title":"Some examples of non-specific immunotherapies include cytokine therapy, adoptive cell transfer and BCG Therapy.  Which of the below statements about the mechanism of action of non-specific immunotherapies are TRUE?  Non-specific therapies stimulate the immune system by: (select all that apply) ","roles":{"textData":{}}},{"id":"si13471","class":"TODO::Senthil","instance":"Text_Caption_99","title":" ","roles":{"textData":{}}},{"id":"si13475","class":"TODO::Senthil","instance":"Text_Caption_100","title":"Targeting and binding to specific tumour antigens and directly neutralising cancer cells which express these antigens. ","roles":{"textData":{}}},{"id":"si13475","class":"TODO::Senthil","instance":"30_54","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si13471_a","class":"TODO::Senthil","instance":"29_53","roles":{"answer":{"title":"Targeting and binding to specific tumour antigens and directly neutralising cancer cells which express these antigens.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13482","class":"TODO::Senthil","instance":"Text_Caption_101","title":" ","roles":{"textData":{}}},{"id":"si13486","class":"TODO::Senthil","instance":"Text_Caption_102","title":"Prompting the growth and division of the body’s own immune cells. ","roles":{"textData":{}}},{"id":"si13486","class":"TODO::Senthil","instance":"32_55","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si13482_a","class":"TODO::Senthil","instance":"31_54","roles":{"answer":{"title":"Prompting the growth and division of the body’s own immune cells.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13493","class":"TODO::Senthil","instance":"Text_Caption_103","title":" ","roles":{"textData":{}}},{"id":"si13497","class":"TODO::Senthil","instance":"Text_Caption_104","title":"Increasing the quantity of immune cells in the body. ","roles":{"textData":{}}},{"id":"si13497","class":"TODO::Senthil","instance":"34_56","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si13493_a","class":"TODO::Senthil","instance":"33_55","roles":{"answer":{"title":"Increasing the quantity of immune cells in the body.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13504","class":"TODO::Senthil","instance":"Text_Caption_105","title":" ","roles":{"textData":{}}},{"id":"si13508","class":"TODO::Senthil","instance":"Text_Caption_106","title":"Increasing the amount of available immune cells by drawing immune cells to the tumour environment. ","roles":{"textData":{}}},{"id":"si13508","class":"TODO::Senthil","instance":"36_57","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"answer":{"title":"dummy title","index":-1,"score":{}}}},{"id":"si13504_a","class":"TODO::Senthil","instance":"35_56","roles":{"answer":{"title":"Increasing the amount of available immune cells by drawing immune cells to the tumour environment.\r","index":"Not implemented","score":{"weight":0}}}},{"id":"si13726","class":"TODO::Senthil","instance":"Button_24","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide13806q9","for":"Slide13806q9"},"textData":{}}},{"id":"si13738","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide13806q9","for":"Slide13806q9"},"textData":{}}},{"id":"si13750","class":"TODO::Senthil","title":"Submit ","roles":{"click":{"subtype":"submit","question":"Slide13806q9","for":"Slide13806q9"},"textData":{}}},{"id":"si13556","class":"TODO::Senthil","instance":"SmartShape_31","title":"Well done!  Non-specific therapies stimulate the immune system by prompting the growth and division of the body’s own immune cells, increasing the quantity of immune cells or drawing immune cells to the tumour environment. Many non-specific therapies are still under investigation and are not widely approved for use in cancer patients.  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"textData":{}}},{"id":"si13575","class":"TODO::Senthil","instance":"SmartShape_32","title":"Almost.   Non-specific therapies stimulate the immune system by prompting the growth and division of the body’s own immune cells, increasing the quantity of immune cells or drawing immune cells to the tumour environment. Many non-specific therapies are still under investigation and are not widely approved for use in cancer patients.  You may wish to review module 2, topic 4: non-specific therapies  Click anywhere to continue. ","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"textData":{}}},{"id":"si13594","class":"TODO::Senthil","instance":"SmartShape_33","title":"You must answer the question before continuing. ","roles":{"click":{"subtype":"button","question":"Slide13806q9"},"textData":{}}},{"id":"Slide13806","class":"Question Slide","instance":"","thumbnail":"","children":["si15441","si15568","SmartShape_30","si13460","si13475","si13486","si13497","si13508","si13726","si13738","si13750","si13594"],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide13806"},"question":{"interactionId":"13410","quizId":377,"title":"Multiple Choice","text":"Some examples of non-specific immunotherapies include cytokine therapy, adoptive cell transfer and BCG Therapy.\r\rWhich of the below statements about the mechanism of action of non-specific immunotherapies are TRUE?\r\rNon-specific therapies stimulate the immune system by: (select all that apply)\r","ikc":false,"type":"graded","interactionType":"choice","ramdomized":false,"correctAnswers":["2","3","4"],"score":{"weight":10,"penalty":0}}}},{"id":"si15463","class":"TODO::Senthil","roles":{}},{"id":"si13895","class":"TODO::Senthil","title":" ","roles":{"click":{"subtype":"button"},"textData":{}}},{"id":"si8470","class":"TODO::Senthil","roles":{}},{"id":"si13904","class":"TODO::Senthil","title":"Maximum Score: ","roles":{"textData":{}}},{"id":"si13908","class":"TODO::Senthil","roles":{}},{"id":"si13912","class":"TODO::Senthil","title":"Accuracy: ","roles":{"textData":{}}},{"id":"si13916","class":"TODO::Senthil","roles":{}},{"id":"si13920","class":"TODO::Senthil","title":"Total Questions: ","roles":{"textData":{}}},{"id":"si13924","class":"TODO::Senthil","roles":{}},{"id":"si13928","class":"TODO::Senthil","title":"Attempts: ","roles":{"textData":{}}},{"id":"si13932","class":"TODO::Senthil","roles":{}},{"id":"si13936","class":"TODO::Senthil","title":"You Scored: ","roles":{"textData":{}}},{"id":"si13940","class":"TODO::Senthil","roles":{}},{"id":"si13944","class":"TODO::Senthil","title":"Correct Questions: ","roles":{"textData":{}}},{"id":"si13948","class":"TODO::Senthil","roles":{}},{"id":"si13952","class":"TODO::Senthil","title":"Immunotherapies - Classes of immunotherapy drugs ","roles":{"textData":{}}},{"id":"Slide8402","class":"Question Slide","instance":"","thumbnail":"","children":[],"roles":{"slide":{"durationInFrames":90},"navigation":{"navid":"Slide8402"}}},{"id":"Pool421","class":"pool","roles":{"pool":{"id":421,"name":"Pool1","questions":[]}}},{"id":"EQ","class":"project","title":"EQ","children":["Slide4531","Slide7159","Slide8115","Slide11080","Slide15079","Slide11016","Slide16061","Slide9659","Slide12297","Slide13313","Slide16620","Slide13806","Slide8402"],"roles":{"quiz":{"id":377,"branched":false,"submitAll":false,"review":true,"questions":["Slide8115q0","Slide11080q1","Slide15079q2","Slide11016q3","Slide16061q4","Slide9659q5","Slide12297q6","Slide13313q7","Slide16620q8","Slide13806q9"],"minScore":0,"maxScore":100,"passScore":80}}}],"contentSettings":{"global":{"branchAware":false},"toc":{"enabled":false},"playbar":{"enabled":false,"cc":false,"playPause":true,"back":true,"forward":true,"rewind":true,"close":true,"mute":true,"progressBar":true}},"contentReporting":{"CCCriteria":"quiz","CCData":{"quizData":"quiz_passed"},"SCCriteria":"quiz","SCData":{"quizData":"quiz_passed"},"exitNormalIfCompleted":false},"toc":[{"id":"Slide4531","title":"Slide 1"},{"id":"Slide7159","title":"Slide 2"},{"id":"Slide8115","title":"Slide 3"},{"id":"Slide11080","title":"Slide 4"},{"id":"Slide15079","title":"Slide 5"},{"id":"Slide11016","title":"Slide 6"},{"id":"Slide16061","title":"Slide 7"},{"id":"Slide9659","title":"Slide 8"},{"id":"Slide12297","title":"Slide 9"},{"id":"Slide13313","title":"Slide 10"},{"id":"Slide16620","title":"Slide 11"},{"id":"Slide13806","title":"Slide 12"},{"id":"Slide8402","title":"Slide 13"}]}